Abstracts tagged "outcomes"

Abstract Number: 1470 • 2015 ACR/ARHP Annual Meeting
A Population-Based Study of Outcomes of Patients with Juvenile Idiopathic Arthritis (JIA) Compared to Non-JIA Subjects
Megan L. Krause¹, J.A. Zamora-Legoff², Cynthia S. Crowson³, Thomas Mason II¹, Theresa Wampler Muskardin² and Eric L. Matteson⁴, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: The impact of juvenile idiopathic arthritis (JIA) is not confined to joint involvement in children but rather widespread effects extending to adulthood. This study…
Abstract Number: 2626 • 2014 ACR/ARHP Annual Meeting
Relationship of Socio-Demographic and Disease Factors with Loss-to-Follow-up and Appointment Noncompliance in Indigent Patients with Systemic Lupus Erythematosus
Angela Pham¹, Gaobin Bao², S. Sam Lim³ and Cristina Drenkard⁴, ¹Rheumatology, Emory University, Atlanta, GA, ²Medicine, Emory University, Atlanta, GA, ³Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ⁴Medicine, Div Rheumatology, Emory University, Atlanta, GA
Background/Purpose . The relationship of medical noncompliance with poor health outcomes has been described in chronic diseases, including systemic lupus erythematosus (SLE). These outcomes are…
Abstract Number: 382 • 2014 ACR/ARHP Annual Meeting
What Is More Predictive of Achieving Remission at 12 Months: The Percentage of Baseline Improvement or the Actual Disease State Achieved at 6 Months?
Edward C. Keystone¹, Carter Thorne², Michael Starr³, Jude Rodrigues⁴, Philip Baer⁵, Regan Arendse⁶, J. Antonio Avina-Zubieta⁷, Denis Choquette⁸, Emmanouil Rampakakis⁹, John S. Sampalis⁹, May Shawi¹⁰, Francois Nantel¹⁰, Allen J Lehman¹¹ and Susan Otawa¹¹, ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁵Private Practice, Scarborough, ON, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁸Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The aim of rheumatoid arthritis (RA) treatment is to optimize symptom control and, when possible, achieve sustained remission. Therefore, identification of clinical signs predicting…
Abstract Number: 2403 • 2014 ACR/ARHP Annual Meeting
From Early Arthritis Clinic to Remission Clinic: Short-Term Outcome and Ultrasonographic-Synovitis Dynamics in Rheumatoid Arthritis Patients in DMARD-Induced SDAI-Remission during Drug-Free Follow-up
Antonio Manzo¹, Francesca Benaglio¹, Garifallia Sakellariou¹, Martina Scarabelli¹, Elisa Binda¹, Barbara Vitolo¹, Serena Bugatti¹, Roberto Caporali² and Carlomaurizio Montecucco¹, ¹Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ²Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose The introduction of DAS-driven intensive treatment strategies in early rheumatoid arthritis (RA) has considerably improved outcome and patients’ quality of life. Previous studies have…
Abstract Number: 375 • 2014 ACR/ARHP Annual Meeting
Evaluation of RAPID3 with Minimal Joint Count and ACR/EULAR Provisional Remission Definitions As Predictors of Future Good Radiographic + Functional Outcome in a Double-Blind, Phase 3, Randomized Controlled Trial of Tocilizumab
Martin J. Bergman¹, Jeffrey Yourish², Jinglan Pei², Jenny Devenport², William Reiss² and Edward Keystone³, ¹Taylor Hospital, Ridley Park, PA, ²Genentech, South San Francisco, CA, ³University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Based on treat-to-target guidelines, the goal of treatment should be remission. Definitions for remission recommended by the ACR/EULAR task force include joint counts and…
Abstract Number: 2153 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcomes in Synovial Fluid Culture ̵ Negative Septic Arthritis
Sarah B. Lieber, Ziv Paz and Robert H. Shmerling, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Delays in diagnosis and treatment of septic arthritis may be associated with significant morbidity. While many patients with suspected or proven septic arthritis are…
Abstract Number: 2037 • 2014 ACR/ARHP Annual Meeting
Incidence and Prevalence of Myasthenia Gravis in Rheumatoid Arthritis Patients with and without Treatment Compared with the General Population
Neil Accortt¹, Mary Anthony¹, Jennifer Schenfeld², Travis Wheeling², Anna Hassebroek², Cynthia O'Malley¹ and Michael Sprafka¹, ¹Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ²Docs Global, Inc, North Wales, PA
Background/Purpose: There is a dearth of information on the incidence rate of myasthenia gravis (MG) in the US and specifically among rheumatoid arthritis (RA) patients. …
Abstract Number: 1670 • 2014 ACR/ARHP Annual Meeting
Characterization of Patients with Lupus Nephritis Included in a Large Cohort from the Spanish Society of Rheumatology Registry of Patients with Systemic Lupus Erythematosus
María Galindo Izquierdo¹, Esther Rodriguez-Almaraz¹, Sabina Perez², José M. Pego-Reigosa³, Jaime Calvo-Alen⁴, Francisco Javier López-Longo⁵, Iñigo Rúa-Figueroa⁶, Alejandro Olivé⁷, Víctor Martínez Taboada⁸, Paloma Vela Casasempere⁹, Mercedes Freire¹⁰, Javier Narváez¹¹, Antonio Fernandez Nebro¹², Jose Rosas¹³, Monica Ibanez Barcelo¹⁴, Esther Uriarte¹⁵, Eva Tomero¹⁶, Antonio Zea¹⁷, Maria Loreto Horcada¹⁸, Vicente Torrente¹⁹, Ivan Castellvi²⁰, Joan Calvet²¹, Raúl Menor Almagro²², Mª Angeles Aguirre²³, Enrique Raya²⁴, Elvira Diez Alvarez²⁵, Tomás Vázquez Rodríguez²⁶, Paloma García de la Peña²⁷, Atusa Movasat²⁸, José Luis Andreu²⁹, Patricia Richi³⁰, Carlos Marras Fernandez-Cid³¹, Carlos Alberto Montilla Morales³², Blanca Hernández-Cruz³³, José Luis Marenco de la Fuente³⁴, Marian Gantes³⁵, Eduardo Ucar³⁶, Juan J. Alegre³⁷, Javier Manero³⁸, Jesús Ibañez Ruán³⁹, Manuel Rodríguez-Gómez⁴⁰, Victor Quevedo⁴¹, José Hernández Beiraín⁴² and Lucía Silva Fernández⁴³, ¹Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, ²Sociedad Española de Reumatología, Research Unit,, Madrid, Spain, ³Instituto de Investigación Biomédica de Vigo (IBIV), Vigo, Spain, ⁴Rheumatology Division, Sierrallana Hospital, Torrelavega, Spain, ⁵Rheumatology, Hospital Gregorio Marañon, Rheumatology, Hospital Gregorio Marañon, Madrid, Spain, ⁶Rheumatology, Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain, ⁷Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, ⁸Rheumatology, Marqués de Valdecilla, Santander, Spain, ⁹Hospital General de Alicante, Alicante, Spain, ¹⁰Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, ¹¹Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ¹²Rheumatology, Hospital Regional Carlos Haya, Biomedical Research Institute of Malaga (IBIMA), Malaga, Spain, ¹³Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, ¹⁴H. Son Llatzer, Palma de Mallorca, Spain, ¹⁵Rheumatology, Hospital de Donosti, San Sebastian, Spain, ¹⁶Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁷Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, ¹⁸Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁹Rheumatology, Hospital Moisès Broggi, Barcelona, Spain, ²⁰Unitat de Reumatologia., Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²¹Hospital Parc Taulí, Barcelona, Spain, ²²Rheumatology, Hospital de Jerez, Jerez de la Frontera, Spain, ²³Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ²⁴Rheumatology, University Hospital San Cecilio, Granada, Spain, ²⁵Rheumatology, Leon Hospital, Leon, Spain, ²⁶Rheumatology, Hospital Lucus Augusti, Lugo, Spain, ²⁷Rheumatology, Hospital Norte Sanchinarro, Madrid, Spain, ²⁸Hospital Príncipe de Asturias, Immune System Diseases/Rheumatology department, Alcalá de Henares, Madrid, Spain, ²⁹Rheumatology, Hospital Puerta de Hierro, Madrid, Spain, ³⁰Hospital Infanta Sofía, Madrid, Spain, ³¹C/ Salvia 11, H. Arrixaca, Alicante, Spain, ³²Rheumatology Department, Hospital Virgen de la Vega, Salamanca, Spain, ³³Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, ³⁴Hospital de Valme. Sevilla, Sevilla, Spain, ³⁵Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, ³⁶Hospital de Basurto, Rheumatology, Bilbao, Spain, ³⁷Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ³⁸Ophthalmology and Rheumatology. Hospital Miguel Servet Zaragoza, Spain, Zaragoza, Spain, ³⁹POVISA, Rheumatology, Vigo, Spain, ⁴⁰Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ⁴¹Rheumatology, Hospital de Monforte, Lugo, Spain, ⁴²Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, ⁴³Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain
Background/Purpose To describe the profile of patients included in RELESSER with histologically confirmed lupus nephritis (LN). Methods RELESSER is a multicentre cross-sectional study, with information…
Abstract Number: 1524 • 2014 ACR/ARHP Annual Meeting
Rituximab Done! What’s Next in RA?
Ulrich A. Walker¹, Veronika K. Jaeger¹, Katerina Chatzidionysiou², Merete Lund Hetland^3,4, Ellen Margrethe Hauge^3,4, Karel Pavelka⁵, Dan C. Nordström⁶, Helena Canhao⁷, Matija Tomsic⁸, Ronald van Vollenhoven² and Cem Gabay⁹, ¹Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ²Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ⁴DANBIO, Center for Rheumatology and Spine Diseases, Glostrup University Hospital, Glostrup, Denmark, Glostrup, Denmark, ⁵Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁶ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, Helsinki, Finland, ⁷Rheumatology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal on behalf of the Rheumatic Diseases Portugal Register, Lisbon, Portugal, ⁸Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia, ⁹University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland
Background/Purpose The optimal strategy to use biologics after rituximab (RTX) in RA is unknown. We therefore aimed to evaluate the effectiveness of different biologics after…
Abstract Number: 1452 • 2014 ACR/ARHP Annual Meeting
Timing of Decisions to Adjust Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting
Yomei Shaw¹, Chung-Chou H. Chang², Marc C. Levesque³, Julie M. Donohue⁴, Kaleb Michaud^5,6 and Mark S. Roberts¹, ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Department of Medicine, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA, ⁴Health Policy & Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁵National Data Bank for Rheumatic Diseases, Wichita, KS, ⁶Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Current guidelines recommend that rheumatoid arthritis (RA) patients with poor response to their current regimen of disease modifying anti-rheumatic drugs (DMARDs) have therapy adjusted…
Abstract Number: 1436 • 2014 ACR/ARHP Annual Meeting
Impact of Depression on Clinical and Social Outcomes in Patients with Rheumatoid Arthritis: Comparative Study in Germany and Brazil
Harriet Morf¹, Olga Malysheva², G da Rocha³, Anna Beatriz Vargas³ and Christoph G. Baerwald², ¹Department of Internal Medicine, University Hospital, Leipzig, Germany, ²Rheumatology, University Hospital, Leipzig, Germany, ³Ambulatório de reumatologia da Policlínica Piquet Carneiro, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
Background/Purpose Rheumatoid Arthritis (RA) can be associated with psychological disorders and especially depression. About 13 – 20 % of patients have clinical significant depression. It…
Abstract Number: 1365 • 2014 ACR/ARHP Annual Meeting
ARE Erosions a Disappearing Feature in Rheumatoid Arthritis (RA)?Joint Damage in Patients with EARLY RA at 10 YEARS after Diagnosis
Juha Asikainen¹, Kalevi Kaarela², Heidi Mäkinen³, Hannu Kautiainen⁴, Pekka Hannonen⁵, Tuomas Rannio⁶ and Tuulikki Sokka¹, ¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ²Jyväskylä Central Hospital, Jyväskylä, Finland, ³Tampere University Hospital, Tampere, Finland, ⁴Medcare Oy, Äänekoski, Finland, ⁵Jyväskylä Central Hospital, Jyvaskyla, Finland, ⁶Kuopio University Hospital, Kuopio, Finland
Background/Purpose: Treatment of rheumatoid arthritis (RA) has improved during the last decade. Also importance of regular monitoring has been emphasized. Our objective was to study…
Abstract Number: 1256 • 2014 ACR/ARHP Annual Meeting
Clinical and Temporal Characterization of Anti-Jo-1 Positive Anti-Synthetase Syndrome: Preliminary Results of an International Multicentre Study
Lorenzo Cavagna¹, Miguel A González-Gay², Santos Castañeda-Sanz³, Franco Franceschini⁴, Paolo Airo⁵, Ilaria Cavazzana⁶, Laura Nuno⁷, Trinitario Pina Murcia², Francisco Javier Lopez Longo⁸, Norberto Ortego-Centeno⁹, Rossella Neri¹⁰, Simone Barsotti¹⁰, Enrico Fusaro¹¹, Simone Parisi¹², Giuseppe Paolazzi¹³, Giovanni Barausse¹³, Luca Quartuccio¹⁴, Elena Bartoloni-Bocci¹⁵, Carlo Selmi¹⁶, Carlo Alberto Scirè¹⁷, Elena Bravi¹⁸, Javier Bachiller Corral¹⁹, Lesley Ann Saketkoo²⁰, Gianluigi Bajocchi²¹, Raffaele Pellerito²², Marcello Govoni²³, Andreas Schwarting²⁴, Christof Specker²⁵, Carlomaurizio Montecucco¹ and Roberto Caporali²⁶, ¹Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ²Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, ³Rheumatology, Hospital Universitario de La Princesa. Madrid. Spain, Madrid, Spain, ⁴AO Spedali Civili, Rheumatology and Clinical Immunology Unit, Brescia, Italy, ⁵Rheumatology and Clinical Immunology, Spedali Civili, AO Spedali Civili, Brescia, Italy, ⁶Rheumatology and Clinical Immunology Unit, AO Spedali Civili, Brescia, Italy, ⁷Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ⁸Rheumatology, Hospital Gregorio Marañón. Madrid, Madrid, Spain, ⁹Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹⁰Rheumatology Unit, University of Pisa, Pisa, Italy, ¹¹Department of Rheumatology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ¹²Rheumatology, Azienda Ospedaliera Città Della Salute e della Scienza, Turin, Italy, ¹³Rheumatology, Santa Chiara Hospital, Trento, Italy, ¹⁴Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ¹⁵Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ¹⁶Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Italy, ¹⁷Italian Society for Rheumatology, Milan, Italy, ¹⁸Internal Medicine, Rheumatology Unit, Ospedale Guglielmo da Saliceto, Piacenza, Italy, ¹⁹Rheumatology, Hospital Ramon y Cajal, Madrid, Spain, ²⁰Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ²¹Department of Internal Medicine, Rheumatology Unit, Arcispedale S Maria Nuova. IRCCS, Reggio Emilia, Italy, ²²Rheumatology, Ospedale Mauriziano, Turin, Italy, ²³Clinical and Experimental Medicine, Section of Rheumatology, University of Ferrara, Ferrara, Italy, ²⁴Rheumatology, University Hospital Johannes-Gutenberg, Mainz, Germany, ²⁵Rheumazentrum Rhein-Ruhr e.V., St. Josef Krankenhaus (Kliniken Essen Süd), Universitätsklinikum Essen, Esssen, Germany, ²⁶Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
Background/Purpose: anti Jo-1 antibodies are the main marker of the antisynthetase syndrome (As), a connective tissue disease chiefly characterized by arthritis (A), myositis (M) and…
Abstract Number: 1059 • 2014 ACR/ARHP Annual Meeting
Patients with RA from Wealthier Countries Perform Better on Clinical Disease Activity Measures, but Tend to Show Worse Person Reported Outcomes
Polina Putrik¹, Sofia Ramiro², Andras Keszei³, Ihsane Hmamouchi⁴, Maxime Dougados⁵, Monika Hifinger⁶, Laure Gossec⁷ and Annelies Boonen⁸, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²Rheumatology, Amsterdam Rheumatology Center, University of Amsterdam & Hospital Garcia de Orta, Almada, Portugal, Amsterdam, Netherlands, ³Medical Informatics, Uniklinik RWTH Aachen University, Aachen, Germany, ⁴Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, ⁵Cochin Hospital, Paris Descartes University, Paris, France, ⁶Rheumatology, MUMC, University Hospital Maastricht, Maastricht, Netherlands, ⁷Rheumatology, Pierre et Marie Curie University, Paris, France, ⁸Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose Inequalities in health between low and high income countries are often reported, but it is not known whether clinical disease activity measures (“objective”) and…
Abstract Number: 811 • 2014 ACR/ARHP Annual Meeting
Biologics in Takayasu Arteritis: Preliminary Data from the French Registry
Arsene Mekinian¹, Chloe Comarmond², Mathieu Resche Regon³, Tristan Mirault⁴, Jean-Emmanuel Kahn⁵, Marc Lambert⁶, Jean Sibilia⁷, Antoine Neel⁸, Miguel Hié⁹, Emmanuel Messas¹⁰, Pascal Cohen¹¹, Geraldine Muller¹², Sabine Berthier¹³, Zahir Amoura¹⁴, Isabelle Marie¹⁵, Christian Lavigne¹⁶, Marie Anne Vandenhende¹⁷, Hervé Devilliers¹⁸, Sébastien Abad¹⁹, Loic Guillevin²⁰, Mohamed Hamidou²¹, Bertrand Godeau²², Patrice Cacoub²³, Olivier Fain²⁴ and David Saadoun², ¹DHU2iB, Internal Medicine Saint Antoine Hospital, PARIS, France, ²DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ³biostatistics Saint Louis Hospital, paris, France, ⁴HEGP vascular department, paris, France, ⁵Internal Medicine, Foch Hospital, Suresnes, France, ⁶Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ⁷Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ⁸INTERNAL MEDICINE, NANTES, France, ⁹Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ¹⁰HEGP hospital Vascular and cardiology Department, paris, France, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹²INTERNAL MEDICINE, DIJON, France, ¹³DIJON HOSPITAL, DIJON, France, ¹⁴Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ¹⁵CHU de Rouen, Rouen, France, ¹⁶CHU d'Angers, Angers, France, ¹⁷Internal Medicine, Bordeaux, France, ¹⁸Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ¹⁹Hôpital Avicenne, Bobigny, France, ²⁰Internal Medicine, Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France, ²¹CHU Hôtel Dieu, Nantes, Nantes, France, ²²Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, ²³Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ²⁴Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France
Background/Purpose The aim of this registry is to determine: (1) the real-life use of various biological targeted treatments in Takayasu arteritis (TA) in France; (2)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].